Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by jammer4444on Jun 25, 2017 11:21am
163 Views
Post# 26402456

RE:RE:Proxy Form - A Call to Action!

RE:RE:Proxy Form - A Call to Action!1)  I also want Majescor to succeed, but Michel already gets paid for sitting on the Board of Majescor (and he gets options too).  Giving him options that derive their success from CARA will not incentivize him to do a better job selling CARDS.  He did not contribute anything to CARA (he is a salesman, not a scientist).

2)  CARDS was an expensive failure for Diagnos, and some of the blame belongs to Michel.  The software cost millions of dollars to develop, but it never produced positive cash flows for the company, and it was sold for less than it cost to develop.  In the article you posted, Michel says that Goldcorp is using Watson AI.  Why aren't they using CARDS instead?

3)  It's a lot of money that is being paid for failure.  I can't understand why.  Those options could easily be worth hundreds of thousands of dollars, but CARDS itself was sold for hundreds of thousands of dollars. My experience in life, is that the simplest explanation is usually correct: Andre is overpaying these Quebecois because he is friends with them. That is why shareholders must send him a message.

Vote Against the Appointment of Jean-Yves Therien to the Board.

Note: I would be happy to give those 1.1 million options to scientists that actually contributed to the development of CARA.  We should reward success, not failure.


Bullboard Posts